Metraipolis › archive › dc_47eb15eb0ed3

The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia — Europe PMC PMID:32053661

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32053661
DOI
10.1371/journal.pone.0229040
License (as archived)
CC0-1.0
Archived
2026-11-09T12:11:56.826Z
SHA-256 of the archived text
21d5bfaf2d6633498d04713207a238698ebb2521c149d45b0b5f07e2925a837d
Stable URL of this page
https://metraipolis.com/documento/dc_47eb15eb0ed3

How to cite

The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia — Europe PMC PMID:32053661 — Europe PMC (en), https://europepmc.org/article/MED/32053661 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_47eb15eb0ed3 (Metraipolis archive dc_47eb15eb0ed3, sha256 21d5bfaf2d6633498d04713207a238698ebb2521c149d45b0b5f07e2925a837d)
BibTeX
@misc{dc47eb15eb0ed3,
  title = {The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia — Europe PMC PMID:32053661},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32053661},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_47eb15eb0ed3; sha256 21d5bfaf2d6633498d04713207a238698ebb2521c149d45b0b5f07e2925a837d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32053661. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: The emergence of pre-extensively and extensively drug-resistant tuberculosis (Pre-XDR/XDR-TB) is the major hurdle for TB prevention and care programs especially in developing countries like Ethiopia. The less emphasis on universal access to laboratory techniques for the rapid diagnosis of TB and drug susceptibility testing (DST) makes the management of MDR-TB a challenge. Early detection of second line anti-TB drugs resistance is essential to reduce transmission of Pre-XDR/XDR-TB strains and adjusting the treatment regimen in MDR-TB. Objective: To determine the prevalence and resistance pattern of Pre-XDR- and XDR-TB among MDR-TB patients in the Amhara region, Ethiopia. Methods: A cross sectional study was carried out in nine MDR-TB treatment centers in the Amhara region. Sputum samples were collected from all pulmonary rifampicin resistant (RR) or MDR-TB patients prior to anti-TB treatment. Lӧwenstein-Jensen (LJ) culture, Ziehl Neelsen (ZN) smear, MTBDRplus and MTBDRsl assays were performed according to the standard procedures. Data were analyzed using SPSS 20 software. Chi-square and/or Fishers exact test was employed. Results: Overall, 6.3% of MDR-TB isolates were resistant to at least one second line drugs. Pre-XDR-TB and XDR-TB isolates accounted 5.7% and 0.6% respectively. Moreover, 3.4% were resistant to FQs and 3.4% were resistant to second line injectable drugs. All isolates were susceptible for low level kanamycin. Almost all pre-XDR-TB strains (90%) were previously treated with anti-TB drugs. Drug resistant Mycobacterium tuberculosis isolates were disproportionately distributed in districts of the Amhara region and the majorities were concentrated in urban areas. Conclusions: The high proportion of MDR-TB patients resistant to at least one second line drug is alarming. Strengthening the laboratory facilities to monitor pre-XDR and XDR-TB patients is crucial. The TB programs need to give emphasis on the effective and rational use of second line drugs for newly diagnosed MDR-TB patients to prevent the emergence of pre-XDR/XDR-TB strains.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-02-13).
Identificativi: PMID 32053661 · PMCID PMC7018133 · DOI 10.1371/journal.pone.0229040.
Pagina: https://europepmc.org/article/MED/32053661 — https://doi.org/10.1371/journal.pone.0229040. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-09T12:07:22.779Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.